<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Murphy, Glenn S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Sugammadex Sprints to the Head of its Class</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">Until recently, the only ways to reverse the action of nondepolarizing muscle relaxant were with neostigmine or other anticholinesterase drugs. Now, a new option—sugammadex—has come on the market in Europe, Japan, and China. This article discusses the safety and efficacy of neostigmine.</style></abstract><number><style face="normal" font="default" size="100%">40</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>